GeneDx Balance Sheet
NASDAQ: WGSHealth CareMedical/Nursing ServicesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
GeneDx financial position
At the end of fiscal 2025, GeneDx reported total assets of $523.7 million, up 24.9% from a year earlier against total liabilities of $215.5 million. Shareholders' equity stood at $308.2 million, or 58.8% of assets. The company held $105.0 million in cash and equivalents against $52.7 million of debt, a net cash position of $52.3 million.
The current ratio (current assets divided by current liabilities) was 2.46, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.17.
Summary generated from market data by MetaCap's automated system. Methodology
GeneDx balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 105.00M | 85.21M | 99.68M | 123.93M | 400.57M | 108.13M | 115.01M |
| Short-Term Investments | 66.28M | 55.97M | 30.47M | 0 | — | — | — |
| Receivables | 74.37M | 37.63M | — | 42.63M | 26.51M | 32.04M | — |
| Inventory | 13.95M | 10.65M | 8.78M | 13.66M | 33.46M | 24.96M | — |
| Total Current Assets | 268.29M | 197.97M | 182.34M | 212.62M | 483.54M | 174.11M | — |
| Property, Plant & Equipment | 45.69M | 32.89M | 32.48M | 51.53M | 62.72M | 63.11M | — |
| Goodwill | 13.52M | 0 | — | — | 0 | 0 | — |
| Intangible Assets | 168.48M | 158.60M | 172.63M | 186.65M | 0 | — | — |
| Total Assets | 523.71M | 419.38M | 418.76M | 490.94M | 554.09M | 251.64M | — |
| Accounts Payable | 2.46M | 7.95M | 10.24M | 46.02M | 44.69M | 26.74M | — |
| Short-Term Debt | 4.54M | 1.21M | 497.00K | 4.75M | 0 | 1.77M | — |
| Total Current Liabilities | 108.91M | 54.82M | 58.82M | 144.30M | 101.28M | 73.44M | — |
| Long-Term Debt | 48.18M | 51.91M | 52.69M | 6.25M | 11.00M | 18.97M | — |
| Total Liabilities | 215.53M | 174.13M | 190.74M | 237.24M | 165.99M | 247.25M | — |
| Shareholders' Equity | 308.18M | 245.25M | 228.02M | 253.71M | 388.10M | -330.05M | -88.71M |
| Retained Earnings | -1.37B | -1.35B | -1.30B | -1.12B | -575.44M | -330.05M | — |
| Total Debt | 52.72M | 53.12M | 53.19M | 11.00M | 11.00M | 20.74M | — |
| Net Cash (Debt) | 118.56M | 88.06M | 76.96M | 112.93M | 389.57M | 87.39M | 115.01M |
| Shares Outstanding | 29.25M | 28.02M | 25.98M | 11.77M | 242.65M | — | — |
This table shows 7 annual periods of GeneDx's balance sheet, from FY 2025 back to FY 2019, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow WGS's reporting calendar. What is a balance sheet?